Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gastrohep.2012.11.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Existence and significance of anti-HLA-C autoantibodies to primary and persistent platelet transfusion refractoriness in patients with hematologic disorders: a retrospective study from a single centre.
Ann Med
December 2025
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
Objectives: Platelet transfusion refractoriness (PTR) is a frustrating clinical problem, and primary and persistent (P/P) PTR who experienced persistent PTR since the first transfusion was failed to be well recognized. This study aims to investigate the incidence and risk factors for P/P PTR.
Methods: Patients with hematologic disorders who underwent HLA high-resolution genotyping and donor-specific HLA antibody or panel reactive antibody (PRA) testing between January 2019 and March 2023 were reviewed.
Treatment of symptomatic bipartite patella in patients <21 years of age: A systematic review and treatment algorithm.
J Child Orthop
December 2024
Department of Orthopaedics, Children's Hospital Boston, Boston, MA, USA.
Purpose: The purpose of this study is to develop an evidence-based algorithm for the management of symptomatic bipartite patella in the pediatric and adolescent population based on a systemic review of the published literature.
Methods: A systematic review of the literature was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines on PubMed and Embase, selecting for studies discussing the management of symptomatic bipartite patella.
Results: Five studies met criteria, involving 315 knees (314 patients, average age 15.
Recalcitrant Pustular Dermatosis Successfully Treated With Prolonged Isotretinoin Therapy.
Cureus
November 2024
Dermatology, Imperial Dermatology, Hollywood, USA.
Isotretinoin (13-cis-retinoic acid) is a well-established systemic treatment for moderate to severe acne vulgaris, renowned for its ability to target multiple contributors to acne pathogenesis. However, its therapeutic potential extends beyond conventional acne management. This case report highlights its efficacy in treating recalcitrant pustular dermatosis, a condition that proved resistant to standard therapies and posed significant diagnostic challenges.
View Article and Find Full Text PDFResolution of Treatment-Refractory Papulopustular Rosacea With Combined Light Source Photodynamic Therapy Using Pre-incubation Nonablative Fractionated Laser Resurfacing.
Cureus
November 2024
Dermatology, University of California, San Diego, USA.
Papulopustular rosacea is an inflammatory subtype of rosacea that can significantly impair patients' quality of life. Available treatment options range from anti-inflammatory topical and oral medications to laser and light therapies. Photodynamic therapy with aminolevulinic acid (ALA-PDT) has emerged as a more recent treatment option for papulopustular rosacea.
View Article and Find Full Text PDFEvaluation of topical 1% posaconazole therapy in refractory fungal keratitis.
Indian J Ophthalmol
January 2025
Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
Purpose: The primary objective was to evaluate the clinical response of refractory cases of fungal keratitis to topical 1% posaconazole therapy.
Methods: Prospective longitudinal non-randomized open label dual-cohort study of 70 eyes of refractory fungal keratitis, 35 were recruited as posaconazole treatment (PCZ) group for topical 1% posaconazole therapy and compared to 35 eyes on conventional antifungal therapy. Study parameters included demographic and treatment details, visual acuity, comprehensive slit-lamp biomicroscopy, clinical photography, ASOCT at recruitment and weekly (week 1, 2, 3 and 4 after treatment initiation).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!